中国肿瘤临床
中國腫瘤臨床
중국종류림상
CHINESE JOURNAL OF CLINICAL ONCOLOGY
2010年
6期
335-337,341
,共4页
刘合利%廖国庆%晏仲舒%张艳仙%尹红玲
劉閤利%廖國慶%晏仲舒%張豔仙%尹紅玲
류합리%료국경%안중서%장염선%윤홍령
直肠间质瘤%诊断%外科手术%伊马替尼
直腸間質瘤%診斷%外科手術%伊馬替尼
직장간질류%진단%외과수술%이마체니
Gastrointestinal stromal tumor%Rectum%Surgical treatment%Imatinib mesylate
目的:直肠间质瘤(Gastrointestinal stromal tumour,GIST)是相对少见的疾病,缺少统一的治疗规范.本研究探讨直肠间质瘤的临床特点、诊断及治疗方法.方法:对中南大学湘雅医院2002年1月~2009年4月间收治的18例直肠GIST的临床资料、治疗方法及结果进行回顾性分析.结果:直肠GIST的临床表现无特异性,多表现为血便或大便次数增多.CT或MRI显示肿块边界清楚,瘤内有出血坏死及无淋巴结肿大.18例标本免疫组化检测CD117和CD34阳性率均100%.低危险性和极低危险性共8例,占44.4%.全组均经手术治疗,行局部切除12例,直肠前切除术(Dixon)3例,腹会阴联合切除术(Miles)3例.术前以伊马替尼新辅助化疗3例,均达部分缓解(partial response,PR),然后均行局部切除.随访1~84个月,5例患者复发转移,其中3例行伊马替尼治疗,病情稳定.另外2例未接受伊马替尼治疗,死亡1例,另1例反复局部切除后行Miles手术.局部切除组与Miles组的无复发生存时间分别为(75.0±8.4)个月和(26.0±11.1)个月(P=0.023).结论:直肠GIST的治疗方法应有别于直肠癌,需要制定个体化的外科治疗方案.对大部分低危险性的患者可通过各种手术路径行局部切除而达到满意效果.伊马替尼新辅助化疗的应用,可使部分直肠GIST患者获得保肛机会.
目的:直腸間質瘤(Gastrointestinal stromal tumour,GIST)是相對少見的疾病,缺少統一的治療規範.本研究探討直腸間質瘤的臨床特點、診斷及治療方法.方法:對中南大學湘雅醫院2002年1月~2009年4月間收治的18例直腸GIST的臨床資料、治療方法及結果進行迴顧性分析.結果:直腸GIST的臨床錶現無特異性,多錶現為血便或大便次數增多.CT或MRI顯示腫塊邊界清楚,瘤內有齣血壞死及無淋巴結腫大.18例標本免疫組化檢測CD117和CD34暘性率均100%.低危險性和極低危險性共8例,佔44.4%.全組均經手術治療,行跼部切除12例,直腸前切除術(Dixon)3例,腹會陰聯閤切除術(Miles)3例.術前以伊馬替尼新輔助化療3例,均達部分緩解(partial response,PR),然後均行跼部切除.隨訪1~84箇月,5例患者複髮轉移,其中3例行伊馬替尼治療,病情穩定.另外2例未接受伊馬替尼治療,死亡1例,另1例反複跼部切除後行Miles手術.跼部切除組與Miles組的無複髮生存時間分彆為(75.0±8.4)箇月和(26.0±11.1)箇月(P=0.023).結論:直腸GIST的治療方法應有彆于直腸癌,需要製定箇體化的外科治療方案.對大部分低危險性的患者可通過各種手術路徑行跼部切除而達到滿意效果.伊馬替尼新輔助化療的應用,可使部分直腸GIST患者穫得保肛機會.
목적:직장간질류(Gastrointestinal stromal tumour,GIST)시상대소견적질병,결소통일적치료규범.본연구탐토직장간질류적림상특점、진단급치료방법.방법:대중남대학상아의원2002년1월~2009년4월간수치적18례직장GIST적림상자료、치료방법급결과진행회고성분석.결과:직장GIST적림상표현무특이성,다표현위혈편혹대편차수증다.CT혹MRI현시종괴변계청초,류내유출혈배사급무림파결종대.18례표본면역조화검측CD117화CD34양성솔균100%.저위험성화겁저위험성공8례,점44.4%.전조균경수술치료,행국부절제12례,직장전절제술(Dixon)3례,복회음연합절제술(Miles)3례.술전이이마체니신보조화료3례,균체부분완해(partial response,PR),연후균행국부절제.수방1~84개월,5례환자복발전이,기중3례행이마체니치료,병정은정.령외2례미접수이마체니치료,사망1례,령1례반복국부절제후행Miles수술.국부절제조여Miles조적무복발생존시간분별위(75.0±8.4)개월화(26.0±11.1)개월(P=0.023).결론:직장GIST적치료방법응유별우직장암,수요제정개체화적외과치료방안.대대부분저위험성적환자가통과각충수술로경행국부절제이체도만의효과.이마체니신보조화료적응용,가사부분직장GIST환자획득보항궤회.
Objective: To assess the clinical features, diagnosis and treatment of gastrointestinal stromal tumor in the rectum.Methods: Records of 18 patients diagnosed as GIST in the rectum between January 2002 and April 2009 were re-viewed and the major clinical features, treatment modalities and outcomes were analyzed.Results: The clinical features of GIST in the rectum were nonspecific.Most patients manifested with bloody stool or changes in bowel habits.CT scan or MRI findings showed necrosis and/or hemorrhage in the tumor and well defined tumor margins.Even in the case of large GIST, no lymphadenopathy was not found, which could be a factor for the differential diagnosis of GIST from other rectal neoplasms.All of the resected tumor specimens showed positive expression of CD117 and CD34 in immunohistochemical staining.Low and very low risk patients accounted for 44.4% (8/18).All patients received surgery.Twelve patients were treated with local excision with different approaches.Anterior resection of the rectum (Dixon) was undertaken in three pa-tients and abdominoperineal resection (Miles) in three patients.Neoadjuvant therapy with imatinib was applied for three pa-tients with partial response.After a median follow-up of 34 months (1~84 months), recurrence and/or metastasis occurred in five patients, and three of them were treated with imatinib.One patient received Miles surgery after repeated local exci-sions.Only one patient died of bone metastasis.Recurrence-free survival (RFS) of the local excision group was longer than that of abdominoperineal resection (APR) group (75.0±8.4 months vs 26.0±11.1 months, P=0.023).Conclusion: The treatment for rectal GIST should be individualized and be different from that of rectal cancer.Treatment decision and choice of procedures should be based on careful preoperative evaluation of tumor size, location, extent and risk level.Most of the anorectal GIST were rated as low-risk in this cohort and could be excised locally by different approaches with satisfactory outcome.Neoadjuvant therapy with imatinib may benefit some patients to obtain the opportunity of sphincter-saving.